TCRT Alaunos Therapeutics, Inc.

-

Alaunos Therapeutics Reported Earnings

Friday, August 14, 2026 · 12:00 AM ET

Alaunos Therapeutics (TCRT) reported a loss of $0.41 per share on revenue of $0.00 million for the . .

Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its non-viral Sleeping Beauty gene transfer platform and its unique cancer hotspot Library, covering common tumor-related mutations in key oncolytic genes including KRAS, TP53 and EGFR.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.41)
Earnings Whisper®
Consensus Estimate
Earnings Surprise
Earnings Growth34.9 %
Reported Revenue
Revenue Estimate
Revenue Surprise
Revenue Growth